Pfizer's new acne cream passes early safety check
NCT ID NCT06671834
First seen Nov 01, 2025 · Last updated Jun 02, 2026 · Updated 27 times
Summary
This early-stage study tested a new topical medicine (PF-07905428) for acne. It involved 52 healthy volunteers and people with moderate to severe acne, aged 18 to 40. The cream was applied daily for 2 to 4 weeks. The main goal was to check safety and how the body processes the drug, not to prove it works yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1, Canada
Conditions
Explore the condition pages connected to this study.